Citations

Showing 10 of 108152 citations.

Abstract 256: Baseline Characteristics and Selected Outcomes in Spontaneous Coronary Artery Dissection Patients: Comparison of Cardiac Rehabilitation Participants and Non-participants
Krittanawong, Chayakrit , Hayes, Sarah , Gulati, Rajiv , Squires, Ray W. , Tweet, Marysia S. , Hayes, Sarah E, Hayes, Sharonne N.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | July 3, 2021 | Volume: 8 | Issue: suppl_2 | Pages: No page available

10.1161/circoutcomes.8.suppl_2.256 Get It

Background: Randomized controlled trials and meta-analyses have demonstrated the benefits of cardiac rehabilitation (CR) in patients with acute myocardial infarction (AMI). Spontaneous coronary artery dissection (SCAD) is an increasingly recognized cause of AMI. However, the benefit of CR has not been well studied in patients with SCAD. Purpose: Our objective was to compare the psychosocial and physiological characteristics and outcomes of CR in SCAD patients who participated in CR compared to those who did not. Methods: We performed a retrospective descriptive analysis of patients with angiographically confirmed SCAD enrolled in the Mayo Clinic SCAD Registry from January 2010 through December 2014 who had completed questionnaires (n=354). Demographics, clinical characteristics, Generalized Anxiety Disorder 7-Item Scale (GAD-7), Patient Health Questionnaire-9 (depression measure; PHQ-9), and details about participants’ CR participation and experience were collected via medical record review and questionnaires. Univariate analyses were performed to determine the differences between baseline characteristics and outcomes according to CR participation status. Results: Mean age of participants at time of SCAD was 46 ± 10 years; 95% were female. Seventy-six percent of participants participated in at least one CR session, and those users averaged 18 ± 12 sessions. A majority of CR participants reported physical and emotional benefits (82% and 75%, respectively). Of those who did not participate in CR, the primary reason was because their healthcare provider did not recommend CR (67%). Other reasons included inadequate transportation (12%), no insurance coverage (8%), cost (2%), no energy (2%), and being too ill (2%). On comparative analyses, CR participants had higher mean GAD-7 scores (4.9 vs. 3.9; p=0.03) and were more likely to increase their amount of exercise (p<0.01). Conclusions: Despite the well-known benefits of CR, in this international registry, only 76% of SCAD patients participated. Lack of recommendation for CR by a health care provider was the primary reason patients did not participate. The majority of patients reported benefits from CR. Higher GAD-7 scores were associated with CR participation, an interesting result requiring further evaluation in a larger or prospective cohort.
Abstract 247: Wikiheart: A Seamless Web-based Program Involving Patients, Clinicians and Researchers
Krittanawong, Chayakrit , Tweet, Marysia S. , Hayes, Sharonne N.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | July 3, 2021 | Volume: 8 | Issue: suppl_2 | Pages: No page available

10.1161/circoutcomes.8.suppl_2.247 Get It

Background: The recent increase in the public’s interest in health matters has been accompanied by greater attention to the development of Web-based programs by many health-related professional and educational services. Wikiheart is a Web-based program that has been designed to narrow the gaps between care and secondary prevention by directly delivering knowledge to patients in their homes and communities. Purpose: To develop a Web-based program aimed at educating patients and targeted to the specific learning needs of patients with heart disease and associated risk factors. Methods and results: This pilot program is relatively easy to use, web-based educational model. It consists of a collaborative feature, the content of which can be easily edited by users, thus enabling powerful information sharing, interactive chat and article discussions. Participants are categorized into two principal groups: (1) invited or volunteer medical professionals; and (2) patients with their own experiences. This program can be used as an information resource for patients and method of real-time communication between healthcare professionals and patients. This virtual program allows patients to engage with each other, share experiences and become part of an online community. As an online interactive medical reference, this program is also intended to help patients with heart disease learn more about their specific conditions and be educated about preventive measures. For patient confidentiality, password protection would be employed and all clinical images and videos would be required to be de-identified. Material that violates patient privacy will be easily removed. Conclusions: Wikiheart aims to enable the sharing of knowledge relevant to secondary prevention and thus improve the quality of care for patients with heart disease or cardiovascular risk factors. If successfully implemented, the program is likely to enhance researchers’, healthcare providers’ and patients’ learning experiences, and communication within digital world, leading to the improvement of clinic outcome and adherence for patients. Further research is needed in order to identify the best approaches to apply these tools and ultimately boost research productivity, learning experience and patient education.
Abstract 236: Trends in Hospitalization for Digoxin Toxicity and Subsequent Outcomes Among Medicare Beneficiaries in the United States, 1999-2011
Nuti, Sudhakar V., Masoudi, Frederick A. , Shah, Nilay D. , Wang, Yun , Freeman, James V. , Murugiah, Karthik , Desai, Nihar R. , Ranasinghe, Isuru , Krumholz, Harlan M.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | July 3, 2021 | Volume: 8 | Issue: suppl_2 | Pages: No page available

10.1161/circoutcomes.8.suppl_2.236 Get It

Objective: To characterize changes in rates of hospitalization for digoxin toxicity and trends in the associated mortality and readmission among older adults over a 12-year period in the United States. Methods: We studied 33,952,331 Medicare fee-for-service beneficiaries 65 years or older with a hospital discharge diagnosis of digoxin toxicity in the United States from 1999 to 2011. Outcome measures were rates of hospitalization for digoxin toxicity; in-hospital mortality; 30-day mortality; and 30-day readmission. Results: There were 20,957 hospitalizations for a principal or secondary diagnosis of digoxin toxicity between 1999 and 2011. The rate declined significantly from 15.2 per 100,000 person-years (95% confidence interval [CI]: 14.7-15.7) in 1999 to 2.1 per 100,000 person-years (95% CI: 1.9-2.3) in 2011 (p<0.001), representing an adjusted annual decline of 17.0% (95% CI: 16.2-17.0) (Figure 1). Between 1999 and 2011, the observed in-hospital and 30-day mortality rates associated with hospitalization for digoxin toxicity declined significantly, from 6.0% (95% CI: 5.2-6.8) to 3.3% (95% CI: 2.0-5.1) (p<0.01) and 14.0% (95% CI: 13.0-15.2) to 10.6% (95% CI: 8.2-13.4) (p<0.05), respectively, representing an annual decline for in-hospital mortality of 5.0% (95% CI: 3.7-7.2) and for 30-day mortality of 4.0% (95% CI: 3.1-5.7). The overall observed 30-day readmission rate declined significantly from 23.5% (95% CI: 22.1-24.9) in 1999 to 18.9% (95% CI: 15.6-22.3) in 2011 (p<0.05), but there was no significant decline in the adjusted annual change in 30-day readmission (1.0%, 95% CI: 0.0-1.7). Conclusions: In a national sample of Medicare beneficiaries, the rate of hospitalization for digoxin toxicity and subsequent mortality declined significantly between 1999 and 2011.
Abstract 152: Persistence of Warfarin versus Dabigatran Therapy in Patients with Atrial Fibrillation: Results from the ORBIT AF Registry
Kim, Sunghee , Shrader, Peter, Blanco, Rosalia , Thomas, Laine , Ansell, Jack , Go, Alan S. , Kowey, Peter R. , Burton, Paul , Piccini, Jonathan P. , Jackson, Larry R. , Fonarow, Gregg C. , Gersh, Bernard J. , Mahaffey, Kenneth W. , Hylek, Elaine M. , Peterson, Eric D.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | July 3, 2021 | Volume: 8 | Issue: suppl_2 | Pages: No page available

10.1161/circoutcomes.8.suppl_2.152 Get It

Introduction: Warfarin and non-vitamin K antagonist oral anticoagulants (NOACs) such as dabigatran are effective for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). However, few analyses have compared persistence rates of warfarin vs. dabigatran-treated patients. Methods: The ORBIT-AF registry enrolled patients with AF from 173 clinical practices across the US. One-year persistence of warfarin vs. dabigatran was defined as treatment at baseline visit and at 1-year follow-up. Multivariable logistic regression analysis was used to identify characteristics associated with warfarin or NOAC persistent use. Results: At baseline, 6.4% (N=459/7,150) were treated with dabigatran and 93.6% (N=6,691/7,150) with warfarin. Patients treated with warfarin at baseline were older (74 vs. 71, p<.0001), had more NYHA class III/IV heart failure (7 vs. 5, p=.0007), lower creatinine clearance (77 vs. 88, p<.0001), higher CHA2DS2-VASc risk scores, and more prior CVA/TIA events (16 vs. 11, p=.003). Patients treated with dabigatran had more severe symptoms (EHRA class III: 20 vs. 14, p<.0001), higher rates of treatment with a rhythm control strategy (42.7 vs. 28.2, p<.0001), more attempts at cardioversion (38.3 vs. 32.1, p<.006), and catheter ablation of AF (9.8 vs. 5.2, p<.0001). At 12 months, adjusted persistence rates for warfarin were higher than dabigatran [82% (80-84) vs. 67% (61-73) p<.0001]. Factors independently associated with one year persistence were: African American race (OR 1.53, 95% C.I. 1.07-2.19, p=0.02), Hispanic race (OR 1.66, 95% C.I. 1.06-2.60), paroxysmal AF (vs. new onset) (OR 1.68, 95% C.I. 1.21-2.33, p=.002), LVH (OR 1.40, 95% C.I. 1.08-1.81, p=.01), persistent AF (vs. new onset) (OR 1.91, 95% C.I. 1.35-2.69, p=.0002), and CHA2DS2-VASc risk scores ≥ 2 (OR 1.94, 95% C.I. 1.18-3.19, p=.009). Conclusion: Persistence rates for warfarin were higher at one year than those on dabigatran. In addition, factors associated with persistence of warfarin include: African American and Hispanic race, type of AF including permanent and persistent, LVH, and CHA2DS2-VASc risk scores ≥ 2.
Abstract 14: Clinical Characteristics and Treatment Patterns of Medicaid Patients with Atrial Fibrillation: Insights From the ORBIT-AF I Registry
O’Brien, Emily C. , Kim, Sunghee , Thomas, Laine , Kowey, Peter R. , Burton, Paul S, Piccini, Jonathan P. , Fonarow, Gregg C. , Mahaffey, Kenneth W. , Gersh, Bernard J. , Peterson, Eric D.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | July 3, 2021 | Volume: 8 | Issue: suppl_2 | Pages: No page available

10.1161/circoutcomes.8.suppl_2.14 Get It

Background: Little is known about whether insurance status affects the presentation and treatment of patients with atrial fibrillation (AF). Methods: We used data from the ORBIT-AF Registry (2010 - 2011), a national, large outpatient registry, to evaluate clinical characteristics and oral anticoagulation (OAC) use. We examined differences in comorbidities and receipt of OAC among patients enrolled in the Medicaid program at baseline compared with those not enrolled in Medicaid. After restricting to patients who were taking OAC, we compared receipt of novel oral anticoagulants (dabigatran or rivaroxaban) versus warfarin by Medicaid status during 2 years of followup. We used logistic regression models adjusting for demographic and clinical covariates to evaluate baseline OAC receipt by Medicaid status. Results: Of 10,133 patients, N=470 (4.6%) were classified as having Medicaid insurance. Compared with those with other insurance, Medicaid patients were younger (70.0 years; IQR=61.0 - 79.0 vs. 75.0 years; IQR=67.0 - 82.0), more likely to be female (53.0% vs. 41.8%), and less likely to be white (58.7% vs. 90.7%; all p<0.001). Medicaid patients had higher rates of smoking, prior stroke/TIA, diabetes, hypertension, and HF. Medicaid patients were less likely to be taking OAC at baseline, a difference that was particularly pronounced for high stroke risk patients (CHADS2>=2, p<0.001; Table). Among those on anticoagulation, Medicaid patients were less likely to receive NOAC over 2 years of followup. In adjusted analyses, Medicaid patients were less likely to receive OAC at baseline, but this difference was not statistically significant (HR = 0.82; 95% CI = 0.61, 1.09). Among untreated patients with CHADS2>=2, Medicaid patients were more likely than patients with other insurance to have “unable to adhere/monitor” listed as a contraindication to OAC (p<0.001). Conclusions: In a contemporary, community-based AF cohort, Medicaid patients had a greater comorbidity burden and higher stroke risk, yet were less likely to receive OAC compared with those with other forms of insurance.
Abstract 1: Incidence and Predictors of Cognitive Decline in Patients with Left Ventricular Assist Devices
Fendler, Timothy J. , Gosch, Kensey , Jones, Philip G. , Bruce, Jared M. , Nassif, Michael E. , Flint, Kelsey M. , Spertus, John A. , Bruce, Jared M, Dunlay, Shannon M. , Allen, Larry A. , Arnold, Suzanne V.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | July 3, 2021 | Volume: 8 | Issue: suppl_2 | Pages: No page available

10.1161/circoutcomes.8.suppl_2.1 Get It

Background: After left ventricular assist device (LVAD) for end-stage heart failure, cognitive function should improve due to increased cerebral perfusion. However, stroke (a well-known LVAD complication) and even subclinical cerebral ischemia may also occur and manifest as transient or permanent cognitive decline. We sought to describe the incidence and predictors of cognitive decline after LVAD using a valid, sensitive assessment tool. Methods: As part of the INTERMACS registry, cognitive function was assessed before LVAD and at each follow-up with the Trailmaking B Test (TBT), where a subject is timed connecting 25 dots labeled with alternating, consecutive numbers and letters (1, A, 2, B, etc.). The TBT can detect several forms of cognitive impairment, including subclinical stroke. Longer times are worse, and cognitive decline was defined as a clinically important increase from baseline to highest follow-up score using Cohen’s D Effect Size (0.2*baseline SD = 13 s). Patients who completed baseline and at least 1 follow-up TBT were included. Multivariable logistic regression was used to examine the association between patient characteristics and cognitive decline after LVAD. Results: Among 1151 LVAD patients, median age was 60-69, 19% were female, and 40% were INTERMACS profile 1-2 (cardiogenic shock or declining despite inotropes) at implant. Among patients with 12-mo follow-up, mean TBT score improved from 126 at baseline to 123 at 1 yr. In the total cohort, 333 (29%) patients had significant cognitive decline within 12 mo of LVAD placement. Increasing age, chronic renal disease, better baseline TBT score (shorter time), and higher INTERMACS profiles (≥ 3; less severe heart failure) were significantly associated with greater odds of cognitive decline (Figure). Conclusion: In a large LVAD registry, cognitive decline occurred in over a quarter of patients in the year after LVAD and was associated with older age, renal disease, higher baseline cognitive function, and more stable heart failure at implant. These results define the frequency of an important adverse event and provide new insights regarding outcomes after LVAD. Future studies are needed to explore the association of transient and permanent cognitive decline with subsequent stroke, health status, and mortality in patients after LVAD placement.
Abstract P86: Predicting Mean Pulmonary Arterial Pressure Using Systemic Arterial Pressure (SPAP)
Steckelberg, Rachel C. , Sorajja, Paul , Ommen, Steven R., Sorajja, Paul , Nishimura, Rick A.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | July 3, 2021 | Volume: 4 | Issue: suppl_2 | Pages: No page available

10.1161/circoutcomes.4.suppl_2.ap86 Get It

Background: The assessment of pulmonary pressure is elementary in the management of patients with pulmonary hypertension. Presently, pulmonary artery systolic pressure (PASP) can be reliably estimated using non-invasive means, but mean pulmonary pressure (MPAP) cannot be derived. The aim of this study was to derive a formula to non-invasively predict MPAP from PASP. Methods: Invasive hemodynamic pressures at steady state were examined in 198 consecutive patients who underwent right heart catheterization in the Mayo Clinic (Rochester, MN). Simple regression techniques were used to determine the relationship between MPAP and PASP separately for derivation and validation samples. Bland-Altman analysis was performed to examine predicted vs. observed MPAP values. Results: Over a wide range of MPAP (10 to 80 mmHg), MPAP and SPAP were strongly related (r2=0.89, n=198). The relation of MPAP to PASP in the derivation sample (n=100; MPAP=0.6133*SPAP + 1.1; r2=0.90) was validated in the test sample with an r2 value of 0.91 for predicted versus observed MPAP (p=x). The relation of predicted vs. observed MPAP values was significant across different degrees of pressure elevation, as well as different etiologies of pulmonary hypertension. Conclusion: MPAP can be accurately predicted from SPAP over a wide pressure range and among different etiologies for pulmonary hypertension. This relation may help to define MPAP non-invasively and assist in the clinical management of patients with pulmonary hypertension.
Abstract P252: Rates of Anticoagulation in Patients with Atrial Fibrillation and Flutter in the Kentucky Women's Health Registry
Mohsin, Rabab, Bailey, Alison , Scantlebury, Dawn C.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | July 3, 2021 | Volume: 4 | Issue: suppl_2 | Pages: No page available

10.1161/circoutcomes.4.suppl_2.ap252 Get It

Introduction: Therapy with warfarin has been shown to decrease the risk of stroke associated with atrial fibrillation and flutter. Current guidelines recommend warfarin therapy for patients with atrial fibrillation who are at intermediate to high risk of thromboembolism. Multiple studies have shown that increasing age and female gender have been associated with underutilization of warfarin. We evaluated women in the Kentucky Women's Health Registry (KWHR) with self-reported atrial fibrillation to determine the rates of warfarin utilization in this population. Methods: Between November 2009 and June 2010, we administered electronic or mailed surveys to KWHR participants who reported an arrhythmia on the Registry questionnaire. Survey questions targeted arrhythmia identification and treatment, medical and social history, pregnancy history and demographics. Herein we analyze the data to determine baseline characteristics of the atrial fibrillation (and flutter) group, including CHADS 2 score and use of anticoagulation. Results: Of the 572 women initially surveyed, 365 responded to the questionnaire, yielding 107 cases of atrial fibrillation and flutter. Baseline characteristics of this group were notable for high education levels and greater than average annual income (see table). Of this population, 36 of 106, (34%) had a CHADS 2 score of >1. Of the women with CHADS 2 scores of >1 who reported their warfarin use, only 10 of 33 [30% (95% confidence intervals, 17-47%)] were receiving warfarin. As expected, the warfarin treated group tended to be older with mean age 73.4 years vs 61.8 years (p<0.001) with a higher CHADS 2 score (p<0.003). Conclusion: Warfarin anticoagulation is underutilized in this group of Kentucky women. This is not attributable to disparities in socioeconomic status given the relatively affluent, highly educated status of the survey respondents. Baseline Characterisitics of Paticipants with Atrial Fibrillation and Flutter Variable Proportion of responders n 95% Confidence Intervals Age (mean years) 63.2 102 61.1-65.3 Hypertension 65% (68) 104 0.56 -0.74 Diabetes 13% (13) 102 0.08-0.21 Congestive heart failure 11% (11) 104 0.06-0 .18 Stroke/TIA 8% (8) 102 0.04-0.15 BMI in kg/m 2 (mean) 28.8 104 27.5-30.1 Aspirin use 49% (51) 104 0.40-0.59 Clopidogrel use 5 % (5) 104 0.02 -0.11 Warfarin use 15% (16) 104 0.10-0.24 CHADS 2 score >1 34% (36) 106 0.25-0 .43 White Race 93% (98) 105 0.87-0 .97 Level of education: Some college or higher 85% (89) 105 0.77-0.90 Median annual household income (Dollars) 60-79,999 101 Inter-quartile range: 40-89,999 (Kentucky median 41,489)
Abstract P205: Comorbities Predict Future Hospitalization Risk in Incident Myocardial Infarction Survivors
Weston, Susan A., Killian, Jill M. , Jaffe, Allan S. , Bell, Malcolm R. , Roger, Véronique L. , Dunlay, Shannon M. , Jaffe, Allan S.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | July 3, 2021 | Volume: 4 | Issue: suppl_2 | Pages: No page available

10.1161/circoutcomes.4.suppl_2.ap205 Get It

Background: Patients are surviving longer after myocardial infarction (MI), but little is known about the occurrence and predictors of subsequent hospitalizations. Methods: We identified all Olmsted Count residents with incident MI from 1987-2008 and evaluated Olmsted County hospitalizations through 2009. ICD-9 codes were used to determine the primary reason for hospitalization. To account for repeated events, Andersen-Gill models were used to examine the predictors of hospitalization post-MI. Patients were censored at death or last follow-up. Results: A total of 2617 patients (mean 67 years, 41% female, 32% with ST-elevation MI) were diagnosed with incident MI from 1987-2007 and survived MI hospitalization. Over a mean follow-up of 7.1 years, 10116 hospitalizations occurred equating to a median of 3 (range 0 to 43) per person. Only 37.5% (n=3793) of hospitalizations were due to cardiovascular causes, and of these, most were due to ischemic heart disease (n= 1865, 49.2%) and heart failure (n= 733, 19.3%). The proportion of non-cardiovascular hospitalizations increased over time and was higher in women than men, but did not differ by ST-segment status. Several factors were associated with the risk of hospitalization after adjusting for year of diagnosis and sex (Figure). Biomarker levels were not predictors of hospitalization risk. Conclusions: Two-thirds of hospitalizations among incident MI survivors in the community are for non-cardiovascular reasons, and this proportion has increased. Comorbidities are important predictors of recurrent hospitalizations. Therapies focused solely on MI management may be insufficient to prevent the majority of future admissions.
Abstract P20: One-Year Hospitalization Costs Associated with Carotid Stenting Versus Endarterectomy: Results from the CREST Trial
Vilain, Katherine , Magnuson, Elizabeth A. , Sternbergh, Charles, Clark, Wayne M. , Begg, Richard J., Sam, Albert D., Weaver, Fred A., Brott, Thomas G. , Li, Haiyan , Cohen, David Jonathan

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | July 3, 2021 | Volume: 4 | Issue: suppl_2 | Pages: No page available

10.1161/circoutcomes.4.suppl_2.ap20 Get It

Background: The CREST trial demonstrated that for patients at standard risk of surgical complications, there was no significant difference in the primary composite outcome of periprocedural death, MI, or stroke, or late ipsilateral stroke between carotid artery stenting (CAS) and carotid endarterectomy (CEA), although CAS had a higher rate of stroke, and CEA had a higher rate of MI. The economic implications of these two strategies are unknown. Methods: We performed a prospective health economic study alongside the CREST trial. Costs were assessed from the perspective of the US health care system in 2008 dollars using a combination of resource-based and event-based methods. Costs for carotid revascularization procedures were based on measured resource use and unit costs derived from a sample of study hospitals. Non-procedural costs for these hospitalizations were estimated using hospital billing data (charges) and cost-center-specific cost-to-charge-ratios. Costs for follow-up events were estimated using national average DRG reimbursements. The primary analysis was based on a modified intention-to-treat population for which the assigned procedure was attempted (n=1212 CAS; 1193 CEA). Results: CAS was associated with higher total procedural costs (Δ=$675, see Table), driven mainly by higher costs for disposable supplies. Length of stay was shorter for CAS, with associated reductions in non-procedural hospital costs (Δ = -$436). Total cost for the index hospitalization remained slightly higher for CAS (Δ=$239) with similar differences at 1 year. Conclusions: For patients at standard risk of surgical complications, total 1-year costs are slightly higher for CAS vs. CEA, driven largely by higher initial procedural costs. Cost-utility analysis will be performed to determine whether differences in quality of life observed in CREST render CAS an economically attractive strategy. CAS (n= 1212) CEA (n=1193) Δ CAS - CEA (95% CI via bootstrap) Index Procedure Costs, $ Excluding MD Fees 6782 ± 1412 5743 ± 1370 1039 (926, 1148) MD Fees 1114 ± 240 1478 ± 108 -364 (-379, -349) Total 7896 ± 1551 7221 ± 1450 675 (555, 800) Index Hospital Stay 7159 ± 5108 7595 ± 7482 -436 (-951, -59) TOTAL Index Hosp Costs 15055 ± 5539 14816 ± 7709 239 (-302, 778) Index Hosp LOS (days) ICU LOS 0.7 ± 1.1 0.8 ± 1.4 -0.1 (-0.24, -0.04) Non-ICU LOS 1.9 ± 3.2 2.2 ± 4.1 -0.2 (-0.55, 0.06) TOTAL LOS 2.6 ± 3.3 3.0 ± 4.5 -0.4 (-0.7, -0.06) 1-year Rehosp Costs: Repeat Revasc - CAS 295 ± 2097 273 ± 2126 -21 (-142, 201) Repeat Revasc - CEA 287 ± 2088 477 ± 2510 -190 (-371, -11) Ipsilateral Stroke 556 ± 3273 384 ± 2580 172 (-75, 402) TIA 48 ± 520 33 ± 487 16 (-25, 56) Death 63 ± 846 45 ± 779 18 (-49, 85) TOTAL Rehosp costs 1321 ± 4827 1293± 4502 28 (-334, 396) TOTAL 1-year costs 16375 ± 7730 16108 ± 9030 267 (-366, 961)